{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:35:47Z","timestamp":1784846147683,"version":"3.55.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","award":["MP3-139793"],"award-info":[{"award-number":["MP3-139793"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0227635","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T18:43:01Z","timestamp":1579200181000},"page":"e0227635","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["Patient preferences for maintenance therapy in Crohn\u2019s disease: A discrete-choice experiment"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-3741","authenticated-orcid":true,"given":"Glen S.","family":"Hazlewood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyanendra","family":"Pokharel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Deardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":true,"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia H.","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"issue":"5","key":"pone.0227635.ref001","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","article-title":"Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data","volume":"156","author":"S Coward","year":"2019","journal-title":"Gastroenterology"},{"issue":"10114","key":"pone.0227635.ref002","first-page":"2769","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"SC Ng","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"pone.0227635.ref003","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"GG Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"pone.0227635.ref004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"NA Molodecky","year":"2012","journal-title":"Gastroenterology"},{"issue":"9","key":"pone.0227635.ref005","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target","volume":"110","author":"L Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"pone.0227635.ref006","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease","author":"S Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"pone.0227635.ref007","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/ajg.2015.321","article-title":"Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse","volume":"110","author":"M Bewtra","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"pone.0227635.ref008","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.rdc.2018.01.009","article-title":"Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete Choice Experiments","volume":"44","author":"GS Hazlewood","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"pone.0227635.ref009","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint Analysis Applications in Health-a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"JF Bridges","year":"2011","journal-title":"Value Health"},{"issue":"2","key":"pone.0227635.ref010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis","volume":"148","author":"GS Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"issue":"11","key":"pone.0227635.ref011","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/rheumatology\/kew280","article-title":"Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment","volume":"55","author":"GS Hazlewood","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"pone.0227635.ref012","unstructured":"Lighthouse Studio v9.0 (Formerly SSIWeb). Orem, Utah: Sawtooth Software, Inc.; 2016. Available from: https:\/\/www.sawtoothsoftware.com\/downloadPDF.php?file=LighthouseStudioManual.pdf."},{"key":"pone.0227635.ref013","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/00365528909091339","article-title":"Classification of inflammatory bowel disease","volume":"170","author":"JE Lennard-Jones","year":"1989","journal-title":"Scand J Gastroenterol Suppl"},{"key":"pone.0227635.ref014","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2017.10.003","article-title":"A Bayesian model that jointly considers comparative effectiveness research and patients' preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations","volume":"93","author":"GS Hazlewood","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"pone.0227635.ref015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","article-title":"The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments","volume":"22","author":"FR Johnson","year":"2019","journal-title":"Value Health"},{"issue":"4","key":"pone.0227635.ref016","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General Methods for Monitoring Convergence of Iterative Simulations","volume":"7","author":"S Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"key":"pone.0227635.ref017","unstructured":"CENTOCOR INC. Remicade (infliximab) [package insert]. Revised June 2018 Nov 21, 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103772s5385lbl.pdf."},{"key":"pone.0227635.ref018","unstructured":"Abbvie Inc. Humira (adalimumab) [package insert]. Nov 21, 2019; (Revised June 2018). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s410lbl.pdf."},{"issue":"12","key":"pone.0227635.ref019","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/17474124.2018.1545574","article-title":"Adverse events in IBD therapy: the 2018 update","volume":"12","author":"SM Quezada","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"pone.0227635.ref020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cgh.2013.08.026","article-title":"Phenotypic features of Crohn's disease associated with failure of medical treatment","volume":"12","author":"GW Moran","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"pone.0227635.ref021","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pec.2012.06.036","article-title":"Option Grids: shared decision making made easier","volume":"90","author":"G Elwyn","year":"2013","journal-title":"Patient Educ Couns"},{"issue":"2","key":"pone.0227635.ref022","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","article-title":"Patient preferences for inflammatory bowel disease treatment objectives","volume":"49","author":"F Casellas","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"4","key":"pone.0227635.ref023","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40271-013-0031-2","article-title":"Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data","volume":"6","author":"M Bewtra","year":"2013","journal-title":"Patient"},{"issue":"8","key":"pone.0227635.ref024","doi-asserted-by":"crossref","first-page":"616","DOI":"10.18553\/jmcp.2010.16.8.616","article-title":"Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management","volume":"16","author":"FR Johnson","year":"2010","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"pone.0227635.ref025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ajg.2017.470","article-title":"Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis","volume":"113","author":"CV Almario","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"pone.0227635.ref026","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/ibd\/izy321","article-title":"Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease","volume":"25","author":"FI Scott","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"pone.0227635.ref027","article-title":"Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents","author":"M Bewtra","year":"2019","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:29:47Z","timestamp":1722320987000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227635"}},"subtitle":[],"editor":[{"given":"Matthew","family":"Quaife","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0227635","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,16]]}}}